Gilead Sciences Buys a New Hepatitis Delta Virus Treatment
Gilead Sciences (NASDAQ: GILD) has taken a step back from expanding its oncology department to bolster an already successful suite of antiviral products. On Thursday morning, the biotechnology giant from California entered a definitive agreement to acquire a German drug developer with a recently approved treatment for hepatitis delta virus (HDV).
Gilead Sciences will acquire MYR GmbH for around $1.4 billion, plus a potential milestone payment of up to $360 million. The purchase gives Gilead Sciences access to Hepcludex, a treatment for HDV that the European Medicines Agency granted conditional approval to this July.
Source Fool.com
